Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 98 от 154

Активно (без набиране) Фаза 3

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Hereditary Angioedema (HAE)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

Начало: 01.12.2024 Край: 01.08.2026 Възраст: от 12 г. Лечение

Argentina, Brazil, Bulgaria +21 Pharvaris Netherlands B.V. NCT06669754

Активно (без набиране) Фаза 3

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Neovascular Age-related Macular Degeneration

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Начало: 27.11.2024 Край: 08.01.2027 Възраст: от 50 г. Лечение

Argentina, Australia, Puerto Rico +1 Ocular Therapeutix, Inc. NCT06495918

Активно (без набиране) Фаза 3

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.

Начало: 25.11.2024 Край: 30.09.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Genmab NCT06635824

Активно (без набиране) Фаза 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese Type 2 Diabetes Mellitus (T2DM)

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Начало: 21.11.2024 Край: 24.09.2026 Възраст: 18–75 г. Лечение

Argentina, Canada, Mexico +3 Carmot Therapeutics, Inc. NCT06628362

Активно (без набиране) Фаза 3

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Cystic Fibrosis

The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).

Начало: 21.11.2024 Край: 30.09.2027 Възраст: от 12 г. Лечение

Australia, Canada, Denmark +3 Vertex Pharmaceuticals Incorporated NCT06460506

Активно (без набиране) Фаза 1/2

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.

Начало: 18.11.2024 Край: 28.08.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Chile +3 Hoffmann-La Roche NCT06624059

Активно (без набиране)

Evaluation of a Simple-Prep Controlled Embolic

Embolization Vascular Tumor Renal Angiomyolipoma Renal Cell Carcinoma +2

The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.

Начало: 18.11.2024 Край: 01.09.2026 Възраст: от 18 г. Лечение

Canada, New Zealand, United States Fluidx Medical Technology, Inc. NCT06453642

Активно (без набиране) Фаза 2

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Idiopathic Pulmonary Fibrosis Progressive Fibrosing Interstitial Lung Disease

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Начало: 15.11.2024 Край: 01.10.2026 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +10 Endeavor Biomedicines, Inc. NCT06422884

Активно (без набиране) Фаза 2

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Chronic Hepatitis B Virus Infection Hepatitis B

The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen.

Начало: 11.11.2024 Край: 31.05.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +16 GlaxoSmithKline NCT06537414

Активно (без набиране) Фаза 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Diabetes Mellitus, Type 2

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Начало: 05.11.2024 Край: 14.07.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +11 Novo Nordisk A/S NCT06534411

Активно (без набиране)

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

Staphylococcus Aureus Bacteremia

Staphylococcus aureus bacteraemia is a frequent and life-threatening infection, despite current standard antibiotic monotherapy. This study aims to clarify the role of fosfomycin as an adjunctive therapy for improving outcomes in patients with this serious infection. Two clinical trials suggested that adjunctive fosfomycin therapy might offer a clinical benefit in certain cases, but the results are inconclusive. We aim to analyse pooled data from these trials in order to identify subgroups of patients that might benefit most from this therapy.

Начало: 01.11.2024 Край: 31.01.2025 Възраст: от 18 г.

Australia, Canada, Spain Hospital Universitari de Bellvitge NCT06695832

Активно (без набиране) Фаза 1

A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

Healthy Participants

The purpose of this study is to test the safety of mRNA-0184 in healthy participants.

Начало: 31.10.2024 Край: 23.06.2026 Възраст: 18–55 г. Фундаментална наука

Australia ModernaTX, Inc. NCT06655870

Активно (без набиране) Фаза 1

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

OPA1 Gene Mutation Autosomal Dominant Optic Atrophy Hereditary Optic Atrophies Kjer Optic Atrophy

A First-in-Human multi-centre, prospective, Phase1a, Single Ascending Dose (SAD) interventional study of PYC-001 in participants with confirmed OPA1 mutation (haploinsufficiency) associated ADOA.

Начало: 31.10.2024 Край: 01.08.2026 Възраст: от 18 г. Лечение

Australia PYC Therapeutics NCT06461286

Активно (без набиране)

A Modified Delphi for ECPR Post Resuscitation Care

Cardiac Arrest

The objective of this study is to generate expert consensus statements on the management of out of hospital cardiac arrest (OHCA) patients treated with extracorporeal membrane oxygenation (ECMO) cardiopulmonary resuscitation (ECPR).

Начало: 30.10.2024 Край: 30.10.2025 Възраст: от 18 г.

Australia Sydney Local Health District NCT06552312

Активно (без набиране) Фаза 2

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Ovarian Cancer

The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.

Начало: 30.10.2024 Край: 26.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Denmark +9 EMD Serono Research & Development Institute, Inc. NCT06433219

Активно (без набиране) Фаза 3

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

Alzheimer's Disease

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

Начало: 24.10.2024 Край: 01.10.2030 Възраст: 55–80 г. Лечение

Australia, Canada, China +7 Eli Lilly and Company NCT06653153

Активно (без набиране) Фаза 1

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

Lymphoma, Non-Hodgkin

The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).

Начало: 22.10.2024 Край: 21.09.2026 Възраст: от 18 г. Лечение

Australia, Spain, Taiwan +1 Janssen Research & Development, LLC NCT06660563

Активно (без набиране)

The Ladera Large Bore Closure Feasibility Study

Vascular Closure Femoral Arteriotomy Closure

This study evaluates the safety and performance of the Ladera Medical suture-mediated large bore closure (LBC) system in gaining post procedure hemostasis in subjects undergoing interventional catheterization procedures using a large-bore procedure sheath.

Начало: 21.10.2024 Край: 01.12.2025 Възраст: от 21 г. Лечение

Australia Ladera Medical NCT06358157

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).

Начало: 21.10.2024 Край: 26.05.2026 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +8 UCB Biopharma SRL NCT06624228

Активно (без набиране) Фаза 2/3

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

Inclusion Body Myositis (IBM)

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.

Начало: 21.10.2024 Край: 01.04.2029 Възраст: от 40 г. Лечение

Australia, United States Abcuro, Inc. NCT06450886

1 … 96 97 98 99 100 … 154